Horizon Pharma Inc. (HZNP) Shares Bought by Capital Fund Management S.A.
Capital Fund Management S.A. boosted its position in Horizon Pharma Inc. (NASDAQ:HZNP) by 157.7% during the second quarter, Holdings Channel reports. The institutional investor owned 54,027 shares of the biopharmaceutical company’s stock after buying an additional 33,060 shares during the period. Capital Fund Management S.A.’s holdings in Horizon Pharma were worth $890,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of HZNP. Deerfield Management Co. raised its stake in shares of Horizon Pharma by 17.6% in the first quarter. Deerfield Management Co. now owns 13,740,261 shares of the biopharmaceutical company’s stock worth $227,676,000 after buying an additional 2,055,460 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Horizon Pharma by 5,195.9% in the first quarter. Franklin Resources Inc. now owns 1,276,730 shares of the biopharmaceutical company’s stock worth $21,155,000 after buying an additional 1,252,622 shares in the last quarter. Bank of Montreal Can purchased a new stake in shares of Horizon Pharma during the second quarter worth $10,193,000. UBS Asset Management Americas Inc. raised its stake in shares of Horizon Pharma by 388.0% in the first quarter. UBS Asset Management Americas Inc. now owns 488,014 shares of the biopharmaceutical company’s stock worth $8,086,000 after buying an additional 388,001 shares in the last quarter. Finally, Bellevue Group AG purchased a new stake in shares of Horizon Pharma during the first quarter worth $5,137,000. Institutional investors and hedge funds own 85.25% of the company’s stock.
Horizon Pharma Inc. (NASDAQ:HZNP) traded up 4.22% on Monday, reaching $19.52. The company had a trading volume of 2,293,606 shares. The firm’s market capitalization is $3.14 billion. Horizon Pharma Inc. has a one year low of $12.86 and a one year high of $23.70. The company’s 50 day moving average is $19.14 and its 200-day moving average is $17.80.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The business had revenue of $257.40 million for the quarter, compared to the consensus estimate of $235.43 million. During the same quarter last year, the business posted $0.39 earnings per share. The company’s revenue for the quarter was up 48.9% on a year-over-year basis. On average, equities research analysts expect that Horizon Pharma Inc. will post $2.15 earnings per share for the current fiscal year.
HZNP has been the topic of a number of research reports. Vetr upgraded Horizon Pharma from a “buy” rating to a “strong-buy” rating in a research report on Monday, October 3rd. Stifel Nicolaus reiterated a “buy” rating and issued a $45.00 price target on shares of Horizon Pharma in a research report on Wednesday, July 6th. Guggenheim reiterated a “buy” rating and issued a $30.00 price target on shares of Horizon Pharma in a research report on Tuesday, August 23rd. Morgan Stanley upgraded Horizon Pharma from an “underweight” rating to an “equal weight” rating and set a $24.00 price target on the stock in a research report on Monday, July 11th. Finally, Brean Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Horizon Pharma in a research report on Thursday, July 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Horizon Pharma currently has an average rating of “Buy” and an average target price of $30.00.
In other news, EVP Jeffrey W. Sherman sold 2,900 shares of the firm’s stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total transaction of $58,000.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 2.10% of the company’s stock.
Horizon Pharma Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma Inc. (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.